Welcome to our dedicated page for Scisparc SEC filings (Ticker: SPRC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SciSparc Ltd. filings document foreign private issuer disclosures for a clinical-stage pharmaceutical company with ordinary shares listed on Nasdaq. The record includes Form 6-K reports and Form 20-F references covering NeuroThera Labs patent and clinical-regulatory updates, cannabinoid-based drug programs, the MUSE endoscopic-system IP portfolio, and hemp seed oil-based product operations.
The company’s SEC materials also describe capital-structure and financing matters, including convertible promissory notes, warrants, resale registration statements, Form F-3 and Form S-8 incorporation, shareholder meeting approvals, reverse-share-split mechanics, Nasdaq continued-listing compliance, governance matters and risk-related disclosure categories.
SciSparc Ltd., through its majority-owned subsidiary NeuroThera Labs, reports that NeuroThera received conditional regulatory approval from the TSX Venture Exchange to acquire approximately 54% of Israeli quantum clinical analytics company CliniQuantum.
Under a March 2026 share purchase agreement, NeuroThera will acquire 56,375 ordinary shares of CliniQuantum in exchange for 56,600,000 NeuroThera common shares, valued at about $9,459,954.20 based on a 20‑day volume-weighted average price. An April 30, 2026 amendment set a minimum deemed price of $0.05 per NeuroThera share for any earn‑out payments, introduced lock‑up arrangements, and extended the outside closing date to June 1, 2026. All 56,600,000 consideration shares will be held in escrow under a Form 5D Escrow Agreement.
SciSparc Ltd. is the subject of Amendment No. 1 to a Schedule 13G/A filed by L.I.A. Pure Capital Ltd., which states the filer owns 5% or less of SciSparc ordinary shares. The filing lists the filer’s address and CUSIP M82618121 and is signed on 05/15/2026 with a form header date of 03/31/2026.
SciSparc Ltd. reports that Nasdaq has issued a conditional compliance letter confirming the company now meets Nasdaq Continued Listing Rule 5550(b)(1) based on its Form 20-F for the year ended December 31, 2025. This resolves an earlier notice that SciSparc failed to satisfy the minimum $2,500,000 stockholders’ equity requirement or the alternative market value and net income tests.
Nasdaq’s staff cautions that if SciSparc does not demonstrate ongoing compliance when it files its next periodic report, the company may face delisting. The 6-K is also incorporated by reference into multiple existing Form F-3 and Form S-8 registration statements.
SciSparc Ltd. is a clinical-stage cannabinoid-focused pharmaceutical company whose main programs, run through majority-owned NeuroThera Labs, target Tourette syndrome, Alzheimer’s-related agitation (SCI-110) and autism spectrum disorder and status epilepticus (SCI-210). It also sells hemp seed oil-based products via Amazon through a subsidiary.
For the year ended December 31, 2025, SciSparc reported a net loss of about $12.6 million, widening from $7.5 million in 2024 and $5.9 million in 2023, and an accumulated deficit of roughly $87 million$5.97 million impairment on loans to AutoMax Motors after a failed merger and AutoMax’s insolvency proceedings. As of December 31, 2025, SciSparc had 365,444 ordinary shares outstanding, following 21‑for‑1 and 9‑for‑1 reverse splits. The company prepares its financial statements under IFRS and has not yet generated revenue from its core pharmaceutical product candidates.
SciSparc Ltd. director Dayan Alon filed an initial statement of beneficial ownership, reporting 3,651 Ordinary Shares of the company. This total includes 3,333 Ordinary Shares issuable from restricted share units vesting in equal quarterly installments of 417 shares beginning on March 18, 2026, and 120 Ordinary Shares issuable from restricted share units vesting in equal quarterly installments of 15 shares beginning on September 30, 2024. Each RSU represents the right to receive one Ordinary Share.
SciSparc Ltd. director Shrem Itschak filed an initial ownership report showing his equity position in the company. He directly holds 11,058 Ordinary Shares and a stock option to buy 6 Ordinary Shares at an exercise price of 21294.0000 per share, expiring on March 1, 2028.
The filing also notes restricted share units. These include 10,000 Ordinary Shares in RSUs vesting in equal quarterly installments of 1,250 shares beginning on March 18, 2026, and 396 Ordinary Shares in RSUs vesting 50 shares quarterly beginning on September 30, 2024. Each RSU converts into one Ordinary Share when vested.
SciSparc Ltd. director Shay Amnon Ben filed an initial Form 3 reporting his beneficial ownership in the company. He directly holds 3,651 Ordinary Shares. This amount includes 3,333 Ordinary Shares issuable from restricted share units vesting in equal quarterly installments of 417 shares beginning on March 18, 2026, and 120 Ordinary Shares issuable from RSUs vesting in equal quarterly installments of 15 shares beginning on September 30, 2024, with each RSU converting into one Ordinary Share.
He also holds a stock option for 1 Ordinary Share at an exercise price of 21,294.0000 that became fully vested on April 21, 2024 and expires on March 1, 2028. The filing does not reflect any buy or sell transactions, only current holdings and award structures.
SciSparc Ltd. director Revach Moshe filed an initial ownership report showing direct holdings of 3,651 Ordinary Shares and stock options over 1 Ordinary Share that are fully vested as of April 21, 2024.
The filing also notes future equity rights from restricted share units. These include 3,333 Ordinary Shares vesting in equal quarterly installments of 417 shares beginning on March 18, 2026, and 120 Ordinary Shares vesting in equal quarterly installments of 15 shares beginning on September 30, 2024, with each RSU delivering one Ordinary Share at vesting.
SciSparc Ltd. CEO and CFO Adler Oz filed a Form 3 reporting his equity holdings in the company. He directly holds 11,058 Ordinary Shares. He also holds a stock option covering 6 Ordinary Shares at an exercise price of 21294.0000, which is fully vested and expires on March 1, 2028.
The filing notes additional equity that may be received through restricted share units. These RSUs cover 10,000 Ordinary Shares vesting in equal quarterly installments of 1,250 shares beginning on March 18, 2026, and 396 Ordinary Shares vesting in equal quarterly installments of 50 shares beginning on September 30, 2024. Each RSU entitles him to receive one Ordinary Share.
SciSparc Ltd. director Weiss Amitay reported initial holdings of 11,058 Ordinary Shares, held directly. This amount includes 10,000 Ordinary Shares issuable from restricted share units vesting in equal quarterly installments of 1,250 shares beginning on March 18, 2026, and 396 Ordinary Shares from restricted share units vesting in equal quarterly installments of 50 shares beginning on September 30, 2024. Amitay also holds a stock option, fully vested on April 21, 2024, to acquire 6 Ordinary Shares at an exercise price of 21294.0000 per share, expiring on March 1, 2028.